Hercend; Thierry

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hercend; Thierry.The latest application filed is for "nucleotide sequence coding for variable regions of beta chains of human t lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses".

Company Profile

0.13.5

Hercend; Thierry - Nogent-sur-Marne N/A FR
Hercend; Thierry - Charenton le Pont FR
Hercend; Thierry - Cambridge MA
Hercend, Thierry - Chareton le Pont FR
Hercend; Thierry - Charenton FR
Hercend; Thierry - Maisons Alfort FR
Hercend; Thierry - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Nucleotide sequence coding for variable regions of .beta. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses Grant 8,709,426 - Hercend , et al. April 29, 2	2014-04-29
Regulation of TNF-alpha Grant 7,960,398 - Miller , et al. June 14, 2	2011-06-14
Caspase inhibitors and uses thereof Grant 7,807,659 - Diu-Hercend , et al. October 5, 2	2010-10-05
Nucleotide Sequence Coding For Variable Regions Of Beta Chains Of Human T Lymphocyte Receptors, Corresponding Peptide Segments And The Diagnostic And Therapeutic Uses App 20080069770 - HERCEND; Thierry ; et al.	2008-03-20
Nucleotide sequences coding for variable regions of .beta. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses Grant 7,294,712 - Hercend , et al. November 13, 2	2007-11-13
Caspase inhibitors and uses thereof App 20070010457 - Diu-Hercend; Anita ; et al.	2007-01-11
Regulation of TNF-alpha App 20040048797 - Miller, Karen ; et al.	2004-03-11
Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies Grant RE38,313 - Faure , et al. November 11, 2	2003-11-11
Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses Grant 6,596,536 - Hercend , et al. July 22, 2	2003-07-22
Caspase inhibitors and uses thereof App 20030096737 - Diu-Hercend, Anita ; et al.	2003-05-22
Nucleotide sequences coding for variable regions of beta chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses App 20030068628 - Hercend, Thierry ; et al.	2003-04-10
Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein Grant 6,143,273 - Faure , et al. November 7, 2	2000-11-07
Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses Grant 5,976,877 - Hercend , et al. November 2, 1	1999-11-02
Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies Grant 5,955,300 - Faure , et al. September 21, 1	1999-09-21
DNA encoding for a protein containing the extracellular domain of lymphocyte activation gene 3 Grant 5,874,250 - Hercend , et al. February 23, 1	1999-02-23
Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use Grant 5,773,578 - Hercend , et al. June 30, 1	1998-06-30
Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells Grant 4,772,552 - Hercend , et al. September 20, 1	1988-09-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.